CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · IEX Real-Time Price · USD
1.140
0.00 (0.00%)
At close: May 16, 2024, 2:22 PM
1.160
+0.020 (1.75%)
After-hours: May 16, 2024, 5:45 PM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors.
The company is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Other |
| Employees | 8 |
| CEO | Brian G. Atwood |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | 650-407-2376 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 206018103 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 6, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 3, 2024 | 8-K | Current Report |
| May 1, 2024 | EFFECT | Notice of Effectiveness |
| May 1, 2024 | 424B5 | Filing |
| May 1, 2024 | 8-K | Current Report |
| Apr 26, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 3, 2024 | PRE 14A | Other preliminary proxy statements |